Financials in USD. Standardized financial statements.
A compact view of how ZIVO Bioscience, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $119,025 | $157,220 | $27,650 | $0 | $0 | $20,000 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -24.3% | +468.6% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $79,091 | $108,268 | $16,040 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $39,934 | $48,952 | $11,610 | $0 | $0 | $20,000 | $0 | $0 | $0 | $0 |
| Gross Margin? | +33.6% | +31.1% | +42.0% | 0.0% | 0.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $9.89M | $13.41M | $7.27M | $8.73M | $9.05M | $8.58M | $8.35M | $6.13M | $6.33M | $3.49M |
| Operating Income? | -$9.85M | -$13.36M | -$7.26M | -$8.73M | -$9.05M | -$8.56M | -$8.35M | -$6.13M | -$6.33M | -$3.49M |
| EBITDA? | -$9.84M | -$13.36M | -$7.26M | -$8.73M | -$9.05M | -$550,054 | -$8.35M | -$6.13M | -$6.33M | -$3.49M |
| Income Before Tax | -$9.89M | -$13.38M | -$7.78M | -$8.75M | -$9.16M | -$9.11M | -$11.51M | -$14.64M | -$10.04M | -$6.06M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $233,281 | $0 | $3.16M | $0 | $0 | $0 |
| Net Income? | -$9.89M | -$13.38M | -$7.78M | -$8.75M | -$9.40M | -$9.66M | -$14.67M | -$14.64M | -$10.04M | -$6.06M |
| EPS? | $-2.59 | $-3.92 | $-4.60 | $-5.58 | $-7.40 | $-11.41 | $-25.47 | $-44.84 | $-34.60 | $-21.73 |
| Diluted EPS? | $-2.59 | $-3.92 | $-4.60 | $-5.57 | $-7.39 | $-11.41 | $-25.47 | $-44.84 | $-34.60 | $-21.73 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality